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Copyright © 2010 JCBN Summary Overintake of sucrose or fructose induces adiposity. Fructose undergoes a strong
Maillard reaction, which worsens diabetic complications. To determine whether Eucalyptus
globulus leaf extract (ELE) suppresses the postprandial elevation of serum fructose concentra-
tions (SFCs) in the portal, cardiac, and peripheral blood after sucrose ingestion, we performed
gas chromatography/mass spectrometry (GC/MS) and measured SFC without any interference
by contaminating glucose in the samples. Fasting Wistar rats were orally administered water
(control group) or ELE (ELE group) before sucrose ingestion. Blood was collected from the
portal vein, heart, and tail. The increase in the SFCs in the portal and cardiac samples 30 min
after sucrose ingestion was lower in the ELE group than in the control group. The coefficient
of correlation between the SFCs in the portal and cardiac samples was 0.825. The peripheral
SFC in the control group progressively increased and was 146 µmol/L at 60 min. This increase
was significantly lower in the ELE group. In contrast, the serum glucose concentrations in the
2 groups were similar. ELE suppressed postprandial hyperfructosemia in the portal, cardiac,
and peripheral circulations. ELE may counteract glycation caused by high blood fructose
concentrations induced by the consumption of fructose-containing foods or drinks.
Key Words:Eucalyptus globulus, serum fructose concentration, postprandial hyperfructosemia,
intestinal fructose absorption, sucrose-tolerance test
Introduction
While starch is the major component of dietary carbo-
hydrate, sucrose is also ingested in large amounts because it
is used in many foods as a sweetener or for other purposes.K. Sugimoto et al.
J. Clin. Biochem. Nutr.
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In addition, the consumption of free fructose has exponen-
tially increased since high-fructose corn syrups (HFCSs)
began to be used as sweeteners in soft drinks and processed
foods [1, 2]. In the United States of America, added sugars
account for more than 30% of the calorie intake of heavy
consumers of soft drinks, and it is presumed that these
consumers ingest approximately 100 g/day of fructose [3].
Fructose is more lipogenic than glucose, and serum
and hepatic triacylglycerol concentrations are significantly
elevated after excessive consumption of sucrose or fructose
[4]. The increased consumption of dietary fructose may be
one of the factors that contributes to the development of
obesity and the abnormalities that accompany the insulin-
resistance syndrome [5–7].
Emerging evidence suggests that excessive consumption
of dietary fructose is an important factor contributing to the
increased prevalence of metabolic syndrome among people
in the United States. In addition, the incidence of soft-drink
ketosis, which is caused by frequent long-term consumption
of commercial beverages containing HFCS, has increased
among young obese men in Japan [8, 9]. A position state-
ment issued by the American Diabetes Association dis-
courages the use of fructose as a sweetener in the diet of a
diabetic patient because fructose adversely affects serum
lipid concentrations [10]. The adverse effects of dietary
sucrose can be prevented by inhibiting the sucrase reaction
in the small intestine [11]. However, sucrase inhibitors are
ineffective when HFCSs are consumed as sweeteners.
The evergreen tree Eucalyptus globulus is native to
Australia and is widely distributed around the world. In South
America and Africa, the leaves of this plant, from which tea
is made, are used as a traditional remedy for diabetes. The
antihyperglycemic effect of E. globulus leaf extract (ELE)
has been confirmed in mice with streptozotocin-induced
diabetes [12]. Furthermore, in a previous study [13], we
reported that the aqueous ethanolic extract of eucalyptus
leaves reduces intestinal fructose absorption and thereby
inhibits the development of fatty liver, the accumulation of
visceral fat, and the increase in serum triglyceride concentra-
tions induced by excessive sucrose consumption, although
the active ingredients of ELE have not yet been identified.
To the best of our knowledge, no agents other than ELE that
specifically inhibit intestinal fructose absorption have been
identified thus far.
In the abovementioned study, we evaluated changes in the
fructose content of the portal blood by using an enzymatic
method [13], which is not highly specific for fructose.
Further, the effect of ELE on circulating blood has not yet
been investigated. Because of these reasons, in this study, we
used a highly sensitive method [14] to accurately measure
the postprandial fructose concentrations in serum derived
from portal and cardiac blood after the oral administration
of sucrose with or without ELE in rats (Study 1). The effects
of ELE on changes in the peripheral serum fructose concen-
tration (SFC) were also estimated (Study 2).
Materials and Methods
Preparation of ELE
ELE was prepared according to a previously described
method [13]. The composition of ELE used in the study
was as follows: total polyphenols measured as tannic acid
equivalents (Folin-Ciocalteu’s method) [15], 30%; moisture
(normal pressure at 105°C and 3 h), 3.0%; ash (produced
by direct ashing), 5.7%; protein measured as leucine
equivalents (Kjeldahl method), 1.6%; and lipid (Röse-
Gottlieb method), 5.7%.
Experimental animals
Male Wistar rats (age, 8 weeks) were purchased from
Kiwa Laboratory Animals (Wakayama, Japan). The animals
were housed in cages (4–5 per cage) under standard labo-
ratory conditions of a 12/12-h light-dark cycle (light phase
beginning at 6.00 AM), an ambient temperature of 23°C ±
2°C, and humidity of 60% ± 10%. All animals received a
standard diet (CE-2, Clea Japan Inc., Tokyo, Japan) and
water ad libitum for at least 1 week prior to the study. All
experimental procedures involving the laboratory animals
were approved by the Animal Care and Use Committee of
Osaka Prefecture University. In this study, we performed the
2 following experiments:
Effect of ELE on changes in postprandial fructose concen-
trations in serum samples derived from portal and cardiac
blood (Study 1)
Rats (body weight, 271 ± 23 g; n = 31) were starved for
16 h. Twenty-five rats were orally administered water
(control group) or an ELE suspension (ELE group; 1 g/kg
body weight, dissolved in 0.5 mL water). After 10 min,
these rats were orally administered a sucrose solution
(2 g/kg body weight, dissolved in 0.5 mL water). Under
diethyl ether anaesthesia, portal and cardiac blood were
sampled from the portal vein (approximately 100 μL) and
the heart (>1 mL) 30 and 60 min after the sucrose ingestion.
Six rats in the fasting state were operated on under diethyl
ether anaesthesia, and their portal and cardiac blood were
sampled.
Effect of ELE on changes in postprandial fructose concen-
trations in peripheral serum (Study 2)
An oral sucrose-tolerance test was conducted using the
same protocol as in Study 1. In brief, rats (body weight,
274 ± 21 g;  n = 10) were fasted and orally administered
water or the ELE suspension. After 5 min, these rats were
orally administered the sucrose solution. Before the admin-
istration of the test sample, and 30 and 60 min after sucroseEucalyptus Inhibits Postprandial Hyperfructosemia
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ingestion, peripheral blood (approximately 0.2 mL) was
sampled from the tail, without anaesthesia, by using 26-G
needles.
Blood variables
The SFCs in the portal, cardiac, and peripheral blood
samples in Studies 1 and 2 were accurately determined
using gas chromatography/mass spectrometry (GC/MS), with
13C6-fructose as an internal standard [14]. The serum glucose
concentrations in the cardiac and portal samples (n = 31)
were measured using the Glucose B test kit (Wako Pure
Chemical Industries, Osaka, Japan).
Statistical analysis
Values are presented as mean ± SD. Statistical analyses
were performed using GB-Stat 5.4 (Dynamic Microsystems,
Silver Spring, MD). We analyzed the fructose and glucose
concentrations in the serum samples derived from portal and
cardiac blood prior to and 30 min after sucrose ingestion
by using one-way analysis of variance (ANOVA), followed
by the Tukey post hoc test. The changes in the peripheral
SFCs were compared between the ELE and control groups
by using two-way ANOVA for repeated measures and
Bonferroni multiple comparison test for post hoc analyses.
Results
Effect of ELE on changes in the postprandial SFCs in samples
derived from portal and cardiac blood (Study 1)
As shown in Fig. 1, the fasting SFCs in the samples
derived from portal (A) and cardiac blood (B) were
114 ± 77 μmol/L and 19.8 ± 7.0 μmol/L, respectively. In the
control group, after oral sucrose administration, the SFC in
the samples derived from portal blood increased transiently,
Fig. 1. Eucalyptus leaf extract (ELE) suppresses the postprandial elevation of serum fructose concentrations in samples derived from
portal (A) and cardiac (B) blood and does not affect the glucose concentrations (C and D) after a sucrose-tolerance test in rats
(Study 1). Mean (SD) fructose and glucose concentrations in the portal and cardiac samples in the control (open circles) and
ELE (closed circles) groups. Fasting rats (n = 31) were orally administered water (control group) or ELE at a dose of 1 g/kg
body weight (ELE group) prior to the ingestion of sucrose (2 g/kg body weight). The fructose and glucose concentrations in the
portal and cardiac samples were determined.K. Sugimoto et al.
J. Clin. Biochem. Nutr.
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peaked at 30 min, and then decreased. These changes were
consistent with the changes in the SFC in the samples
derived from cardiac blood, except that the SFC in the
cardiac samples at 30 min was considerably lower than that
in the portal samples. In the ELE group, the increase in the
SFC in the portal samples was significantly lower than that
in the control group (p<0.05), and the inhibition ratio at
30 min was 53%. The SFC in the cardiac samples was also
lower than that in case of the control group, but not signifi-
cantly so. The correlation between the SFCs in the portal and
cardiac samples is shown in Fig. 2. The coefficient of
correlation between these variables (n = 31) was 0.825.
The changes in the serum glucose concentrations in both
portal and cardiac samples during the sucrose-tolerance test
were similar in the 2 groups (Fig. 1C and D).
Effect of ELE on changes in the postprandial fructose
concentrations in the serum samples derived from peri-
pheral blood (Study 2)
The time course of the peripheral SFCs during the
sucrose-tolerance test is shown in Fig. 3. The fasting SFCs
in the 2 groups almost equaled the SFC in the cardiac
samples in Study 1 (approximately 20 μmol/L). After the
sucrose load, the peripheral SFC in the control group
progressively increased and reached 146 ± 29 μmol/L at
60 min. Although the peripheral SFCs in the ELE group also
increased, the increment was significantly lower, and the
inhibition ratios were 90% and 65% at 30 and 60 min,
respectively (p<0.05).
Discussion
The results of Studies 1 and 2 show that during the
sucrose-tolerance test, ELE suppressed the increase in
postprandial SFCs in not only portal samples but also cardiac
samples.
Changes in the fructose concentration in the peripheral
blood after oral fructose administration have been examined
in rats by using an enzymatic method [16] and in human
subjects by using a colorimetric method [17–21]. In the case
of these methods, other reducing substances in the blood
complicate the interpretation of the fructose analysis; for
example, high glucose content interferes with the measure-
ment of fructose concentrations. Thus, these substances
reduce the sensitivity and accuracy of these methods. In the
case of the enzymatic method used by Sugimoto et al. [13],
the calibration curve was deflected at low fructose concen-
trations because of coexisting reducing substances (data not
shown). It is necessary to measure blood fructose concentra-
tions by using highly sensitive measurement methods because
the fructose concentration in peripheral blood is generally
low [18, 19]. We developed a highly sensitive method for the
measurement of SFCs: complete exclusion of blood glucose
by using a normal-phase high-performance liquid chromato-
graphy (HPLC) column followed by GC/MS, with 13C6-
Fig. 2. Correlation between the serum fructose concentrations
in the portal and cardiac samples during the sucrose-tol-
erance test (Study 1). Individual fructose concentrations
in the portal and cardiac samples in both the control and
eucalyptus leaf extract (ELE) rats (open circles). The co-
efficient of correlation was 0.825 (n = 31).
Fig. 3. Eucalyptus leaf extract (ELE) significantly suppresses
the postprandial elevation of the peripheral serum
fructose concentration after the sucrose-tolerance test in
rats (Study 2). The mean (SD) peripheral serum fructose
concentrations in the control (open circles) and ELE
(closed circles) groups are shown. Fasting rats (n = 10)
were orally administered water (control group) or ELE at
a dose of 1 g/kg body weight (ELE group) prior to the
ingestion of sucrose (2 g/kg body weight). The fructose
concentrations in the peripheral serum sampled from the
tail were determined. *p<0.05 compared to the control
group.Eucalyptus Inhibits Postprandial Hyperfructosemia
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fructose as an internal standard [14]. By using this method,
we found that the fasting SFCs in the samples derived from
the cardiac (Study 1) and peripheral blood (Study 2) of rats
were approximately 20 μmol/L at the baseline and nearly
equaled previously reported fasting SFCs in humans [14, 22].
After oral sucrose administration, the SFC in the portal
samples in the control group rapidly increased. In our study,
ELE suppressed the increase in the SFC after sucrose admin-
istration (Fig. 1A). The changes in the SFCs in the cardiac
samples (Fig. 1B) were consistent with the changes in the
portal samples (Fig. 1A); ELE also suppressed the elevation
in the postprandial fructose concentrations in the cardiac
samples. Since the SFCs in the portal and cardiac samples
were highly correlated (Fig. 2), it was possible to evaluate
the suppressive effect of ELE on the increase in postprandial
blood fructose concentrations by using cardiac blood, which
can be collected in large amounts (>1 mL). The increase in
the peripheral SFCs in the ELE group was significantly
lower than that in the control group (Fig. 3). Thus, the
suppressive effect of ELE can also be evaluated by sampling
peripheral blood. In contrast, the changes in the serum
glucose concentrations in the cardiac and portal samples did
not differ between the ELE and control groups during the
60-min oral sucrose-tolerance test (Fig. 1C and D). A
previous study has reported that ELE does not inhibit
intestinal glucose absorption in rats, and that it inhibits
sucrase activity in vitro to a lower extent than other inhibitors
such as (+)-catechin and (−)-epigallocatechin 3-O-gallate
[13]. These results reinforce the hypothesis [13] that ELE
specifically inhibits fructose absorption in the intestine.
However, the possibility that ELE only delays fructose
absorption in the intestine and has little effect on the total
amount of absorbed fructose cannot be ruled out because we
did not examine the area under the blood concentration-time
curve of fructose in this study.
Fructose transported to the liver is rapidly metabolized
because the metabolic pathway involved bypasses the main
rate-controlling step in glycolysis, which is catalyzed by 6-
phosphofructokinase [23]. Consequently, the postprandial
fructose concentrations in the peripheral blood are lower
than the glucose concentrations [18,  19]. In the control
group, the increase in the postprandial SFC in the peripheral
samples (Fig. 3) was much lower than that in the portal
samples (Fig. 1A). Therefore, we inferred that the liver
actively metabolizes fructose. Further, we found that in the
control group, the administration of sucrose at a dose of
2 g/kg body weight increased the peripheral SFC to more
than 7-fold the fasting concentration. In human subjects,
the SFC after the administration of fructose at a dose of
0.75 g/kg body weight has been reported to be approxi-
mately 600 μmol/L [21]. In a previous study, we reported the
case of a patient who had an SFC of 517 μmol/L because of
excessive daily and long-term consumption of soft drinks
[9]. It appears that a large amount of free fructose is released
in the systemic circulation by the liver, without being
metabolized.
SFCs can significantly affect protein glycation [24]
because fructose is more reactive than glucose in the
Maillard reaction by at least 1 order of magnitude [25, 26].
Clinical and rodent studies have shown that dietary fructose
consumption increases fructated advanced glycation end-
products (AGEs) in serum and various tissues [27–29]. ELE
may prevent such glycation by lowering postprandial eleva-
tion of blood fructose concentration.
The active ingredients of ELE have not yet been identified.
Various components have been isolated from ELE such as
hydrolyzable tannins [30–32], flavonol glycosides [32, 33],
β-diketones [34], and phloroglucinol derivatives [35, 36].
ELE was solubilized in water and subjected to extraction
with diethyl ether, ethyl acetate and n-butanol; the n-butanol
extract inhibited intestinal fructose absorption (data not
shown). We speculate that the active component(s) of ELE
are not β-diketones because these compounds were not
identified in our n-butanol extract. Further investigation is
required to identify the substance(s) in ELE that inhibit
intestinal fructose absorption.
In conclusion, ELE can potentially prevent and treat
disorders induced by excessive fructose intake. Further, the
suppressive effect of ELE on the increase in postprandial
blood fructose concentrations may be evaluated in human
subjects by using peripheral blood samples.
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